Cortes Highlights Second-Generation TKIs for Frontline Therapy in CML

Jorge Cortes sees the future of CML care in earlier treatments. “I think that a lot of the focus now is to see if we should do some interventions early on to try to optimize the number of patients who get to the deepest molecular responses and that would, at some point, be eligible for treatment discontinuation,” he said in an interview with Targeted Oncology.